Low-Dose Ara-C by Continuous Infusion in the Treatment of Acute Non-Lymphocytic Leukemia (ANLL) and Myelodysplastic Syndrome (MDS)

  • Farida Chaudhri
  • Steven L. Allen
  • Philip Schulman
  • Willi Kreis
  • Daniel R. Budman
  • Lora Weiselberg
  • Vincent Vinciguerra

Abstract

Thirteen patients with acute non-lymphocytic leukemia (ANLL) or myelodysplastic syndrome (MDS) were treated with low-dose cytosine arabinoside (Ara-C) 20 mg/m2/day by continuous intravenous infusion for 21 days. Seven patients attained complete remissions (CR) and two patients had partial remissions (PR). Two patients required two courses of treatment before attaining CR. Two of four patients with abnormal cytogenetics also achieved complete response with reversion of cytogenetic abnormalities to normal. All patients who responded showed profound pancytopenia with marked hypoplasia of bone marrow. The universal occurrence of pancytopenia and reversion of cytogenetic abnormalities to normal suggests that low-dose Ara-C is cytotoxic and may not act as a differentiating agent.

Keywords

Toxicity Catheter Leukemia Anemia Diarrhea 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lotem, J, Sachs, L., Different Blocks in the Differentiation of Myeloid Leukemic Cells. Proc. Nat. Acad. Sci.1974, 71: 3507–3511.CrossRefGoogle Scholar
  2. 2.
    Krystosek, A., Sachs, L., Control of Lysozyme Induction in the Differentiation of Myeloid Leukemic Cells. Cell1976: 9: 675–584.CrossRefGoogle Scholar
  3. 3.
    Sachs, L. The Differentiation of Myeloid Leukemia Cells: New Possibilities for Therapy. Br. J, Haem.1978; 40: 509–517.CrossRefGoogle Scholar
  4. 4.
    Cohen, J. R., Creger, W. P., Greenberg, P.L., Schrier, S.L. Sub-acute Myeloid Leukemia: A Clinical Review. Am. J. Med.1979: 66: 959–66.CrossRefGoogle Scholar
  5. 5.
    Crosby, W.H., To Treat or Not to Treat: Acute Granulocytic Leukemia. Arch. Int. Med.1968; 122: 79.CrossRefGoogle Scholar
  6. 6.
    Cooperative Group for the study of aplastic and refractory anemia with excess of blast cells: Prognostic factors and effect of treatment with androgen or Cytosine Arabinoside: Results of prospective trial in 58 patients. Cancer1979; 44: 1976–82.Google Scholar
  7. 7.
    Baccarani, M., Tura, S, Differentiation of Myeloid Leukemic Cells: New Possibilities for Therapy. Br. J. Haem.1979; 42: 485–487.CrossRefGoogle Scholar
  8. 8.
    Housset, M., Daniel, M.T., Degos, L., Small Doses of Ara-C in the Treatment of Acute Myeloid Leukemia: Differentiation of Myeloid Leukemia Cells. Br. J. Haem.1982; 51: 125–129.CrossRefGoogle Scholar
  9. 9.
    Maloney, W.C., Rosenthal, D.S., Treatment of Early Acute Non-lymphatic Leukemia with Low Dose Cytosine Arabinoside. Haem. and Blood Trans.1981; 26: 59–62.Google Scholar
  10. 10.
    Castaigne, S., Daniel, M.T., Degos, L. Does Treatment with Ara-C in Low Dosage Cause Differentiation of Leukemic Cells? Blood1983; 62: 85–86.Google Scholar
  11. 11.
    Wisch, J.S., Giffin, J, Kufe, D. Response of pre-leukemic syndromes to continuous infusion of low dose Ara-C. N. England J. Med.1983; 239: 1599–1605.CrossRefGoogle Scholar
  12. 12.
    Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D. A.G., Gralnick, H.R., Sultan, C., The French-American-British (FAB) Cooperative Group. Proposals for the Classification of the Myelodysplastic Syndromes. Br. J. Haem.1982; 51: 189 - 199.Google Scholar
  13. 13.
    Piall, E.M., Aherne, G.W., Marks, V.M., A Radioimmunoassay for Cytosine Arabinoside. Br. J. Cancer1979; 40: 548–556.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Farida Chaudhri
    • 1
    • 2
  • Steven L. Allen
    • 1
    • 2
  • Philip Schulman
    • 1
    • 2
  • Willi Kreis
    • 1
    • 2
  • Daniel R. Budman
    • 1
    • 2
  • Lora Weiselberg
    • 1
    • 2
  • Vincent Vinciguerra
    • 1
    • 2
  1. 1.Don Monti Division of OncologyDepartment of Medicine North Shore University HospitalManhassetUSA
  2. 2.Cornell University Medical CollegeNYUSA

Personalised recommendations